Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefpirome + sulbactam is a parenteral fixed-dose combination antibiotic consisting of cefpirome, a fourth-generation cephalosporin, and sulbactam, a beta-lactamase inhibitor. Cefpirome provides broad-spectrum bactericidal activity against both Gram-positive and Gram-negative bacteria, including *Pseudomonas aeruginosa* and members of the *Enterobacteriaceae* family. It works by binding to and inhibiting penicillin-binding proteins (PBPs), which are essential for bacterial cell wall synthesis. Sulbactam acts as a suicide inhibitor of various beta-lactamase enzymes, thereby protecting cefpirome from enzymatic degradation and extending its therapeutic spectrum to include beta-lactamase-producing resistant strains. This combination is primarily used for the treatment of severe systemic infections, such as sepsis, pneumonia, and complicated urinary tract infections, particularly when multi-drug resistance is suspected.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefpirome + sulbactam.